Skip to content

Clinical Study on the Efficacy of Multivitamin Peptides in Improving Hypoproteinemia in Patients

A Prospective Non-Randomized Parallel-Group Controlled Trial of Multi-Protein Peptide Intervention for Hypoproteinemia in Patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122573
Enrollment
Unknown
Registered
2026-04-15
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoproteinemia

Interventions

Control group:Conventional dietary guidance
Study group:Multivitamin peptide enteral nutritional intervention

Sponsors

Wuxi people’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.According to the criteria specified in the 8th edition of Internal Medicine, a diagnosis of hypoproteinemia? is confirmed when serum albumin is < 35 g/L; 2.Judged by the clinical physician, the disease causing hypoproteinemia is in a relatively stable phase; 3.Voluntarily participated in the study and signed the informed consent form; 4.Adults aged 18-80, both men and women.

Exclusion criteria

Exclusion criteria: 1.Known history of allergy or intolerance to any ingredient in this protein supplement; 2.Pregnant and lactating women, as well as individuals planning to become pregnant during the trial period; 3.Individuals with severe heart disease, severe liver failure (e.g., Child-Pugh class C), severe renal insufficiency (e.g., requiring dialysis), or other severe organic diseases; 4.Individuals currently using immunosuppressants such as glucocorticoids or immunosuppressive agents (e.g., cyclosporine, tacrolimus); 5.Individuals with albumin/globulin (A/G) ratio 3.5g/24h); 9.Individuals with moderate or severe anemia; 10.Individuals in a state of low immunity, such as AIDS patients or those with other immunodeficiency diseases; 11.Individuals with severe metabolic disorders, such as poorly controlled diabetes (HbA1c > 9%) or thyroid dysfunction (e.g., hyperthyroidism or hypothyroidism); 12.Patient for whom the specific cause of hypoproteinemia cannot be determined; 13.Investigator deems the subject to have poor compliance, or the investigator believes the subject is unsuitable to participate in this trial for any other reason;

Design outcomes

Primary

MeasureTime frame
Liver function;

Secondary

MeasureTime frame
Immune Function;Haematological parameters;Kidney function;Grip strength;Nutritional Prognostic Index;

Countries

China

Contacts

Public ContactQuyan Zhou

Wuxi people’s Hospital

qunyan224@163.com+86 13358111996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026